Arrivent Biopharma Inc (AVBP)

04:00 AM

ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data - MyChesCo

04:00 AM

Jul 22, 2025

ArriVent BioPharma Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is ArriVent BioPharma Inc. a good long term investmentOverwhelming financial success - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada

Jul 22, 2025

Jul 22, 2025

What drives ArriVent BioPharma Inc. stock priceAccelerated wealth expansion - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What analysts say about ArriVent BioPharma Inc. stockFree AI-Backed Trading Signals - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What makes ArriVent BioPharma Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser

Jul 22, 2025

Jul 21, 2025

ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com UK

Jul 21, 2025

Jul 21, 2025

ArriVent Biopharma announces data from its FURVENT Phase 3 study - TipRanks

Jul 21, 2025

Jul 21, 2025

ArriVent expects topline data from lung cancer drug trial in early 2026 By Investing.com - Investing.com South Africa

Jul 21, 2025

Jul 21, 2025

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - The Manila Times

Jul 21, 2025

Jul 21, 2025

New Strong Sell Stocks For July 21st - Barchart.com

Jul 21, 2025

Jul 21, 2025

New Strong Sell Stocks for July 21st - The Globe and Mail

Jul 21, 2025

Jul 18, 2025

Is ArriVent BioPharma Inc. stock a growth or value playDaily Price Surge List - Newser

Jul 18, 2025

Jul 18, 2025

P 500Low Risk Trade Timing Signals - Newser

Jul 18, 2025

Jul 16, 2025

60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest

Jul 16, 2025

Jul 15, 2025

Why ArriVent BioPharma Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025

Jul 14, 2025

ArriVent BioPharma Conducts $75 Million Public Offering - Global Legal Chronicle

Jul 14, 2025

Jul 12, 2025

ArriVent BioPharma (NASDAQ:AVBP) Given a $33.00 Price Target by The Goldman Sachs Group Analysts - Defense World

Jul 12, 2025

Jul 12, 2025

The Goldman Sachs Group Reiterates “Buy” Rating for ArriVent BioPharma (NASDAQ:AVBP) - Defense World

Jul 12, 2025

Jul 10, 2025

How To Trade (AVBP) - news.stocktradersdaily.com

Jul 10, 2025

Jul 10, 2025

ArriVent BioPharma stock rating resumed at Buy by Goldman Sachs - Investing.com Canada

Jul 10, 2025

Jul 08, 2025

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering - Mintz

Jul 08, 2025

Jul 03, 2025

ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval - Investing.com Canada

Jul 03, 2025

Jul 03, 2025

ArriVent BioPharma Announces $75 Million Public Offering - The Globe and Mail

Jul 03, 2025

Jul 02, 2025

Latham & Watkins Advises on ArriVent’s US$75 Million Common Stock Offering and Pre-Funded Warrants - Latham & Watkins LLP

Jul 02, 2025

Jul 02, 2025

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

Jul 02, 2025

Jul 01, 2025

ArriVent BioPharma Plans $75 Million Public Offering - MarketScreener

Jul 01, 2025

Jul 01, 2025

ArriVent BioPharma announces $75 million public offering By Investing.com - Investing.com UK

Jul 01, 2025

Jul 01, 2025

ArriVent BioPharma's $75M Offering: Navigating Dilution for Oncology's Next Breakthrough - AInvest

Jul 01, 2025

Jun 28, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Buy” by Brokerages - Defense World

Jun 28, 2025

Jun 27, 2025

Research Analysts Offer Predictions for AVBP FY2025 Earnings - Defense World

Jun 27, 2025

Jun 25, 2025

ArriVent BioPharma (NASDAQ:AVBP) Given Buy Rating at Guggenheim - Defense World

Jun 25, 2025

Jun 24, 2025

Latest Analyst Updates: June 24th, 2025 - The Globe and Mail

Jun 24, 2025

Jun 24, 2025

Clear Street initiates ArriVent BioPharma stock with Buy rating By Investing.com - Investing.com Canada

Jun 24, 2025

Jun 23, 2025

Citi ups ArriVent price target to $40, adding ‘upside 90-day short-term view’ - TipRanks

Jun 23, 2025

Jun 23, 2025

ArriVent BioPharma (AVBP) Presents Promising Firmonertinib Data in Lung Cancer Study | AVBP Stock News - GuruFocus

Jun 23, 2025

Jun 23, 2025

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study - The Manila Times

Jun 23, 2025

Jun 20, 2025

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC - The Manila Times

Jun 20, 2025

Jun 20, 2025

ArriVent to Unveil Next Steps for Breakthrough EGFR PACC Lung Cancer Drug Firmonertinib - Stock Titan

Jun 20, 2025

Jun 13, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases New Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Jun 13, 2025